Document 2606
 DOCN  M94A2606
 TI    Is hepatitis B vaccine effective in HIV-positives? Changes in hepatitis
       markers during the AIDS epidemic.
 DT    9412
 AU    Ifft FN; Greater Phila. Health Action, PA 19147.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):266 (abstract no. PB0493). Unique
       Identifier : AIDSLINE ICA10/94369969
 AB    METHOD: Retrospective analysis of HIV+ patients' presenting Hepatits
       serologies: 1983-93, and prospective evaluation of vaccine in subset of
       Hep B marker negatives. RESULTS: Prior to 1988, 74% of all newly
       presenting HIV+ patients had Hep-sAG (14%) or sAB (60%); 8% had core-AB
       only; 11% had no markers. This pattern has changed progressively with
       time: 1993 figures are 15%; 18%; 21.5%: and 35.4% respectively. No
       patients with initial CD-4 less than 500 responded to vaccine.
       CONCLUSION: Serologic response to Hep BsAg is compromised by
       pre-existing HIV infection; vaccination may not be cost-effective. This
       issue deserves further investigation.
 DE    Cost-Benefit Analysis  *Disease Outbreaks  Hepatitis
       B/*IMMUNOLOGY/PREVENTION & CONTROL  Hepatitis B Antibodies/BLOOD
       Hepatitis B Core Antigens/BLOOD  Hepatitis B Surface Antigens/BLOOD
       Hepatitis B Vaccines/ADMINISTRATION & DOSAGE/ECONOMICS/  *IMMUNOLOGY
       Human  HIV Seropositivity/*IMMUNOLOGY  Retrospective Studies  MEETING
       ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).